CSL Limited CSL Limited

CSL Limited

CSL

株式のランク #363
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
株価
$138.58
時価総額
$66.50B
変化(1日)
0.72%
変化(1年)
-2.29%
国
AU
取引 CSL Limited (CSL)

カテゴリー

Healthcare
CSL Limited(CSL)のP/B比率
October 2026 時点のP/B比率 TTM: 4.21
CSL Limited の最新の財務報告および株価によると、現在のP/B比率(TTM)は 4.21 です。2024 年末時点でのP/B比率は 5.43 でした。
CSL Limited の P/B 比率の履歴(2000 ~ 2026)
各年末時点のP/B比率
年 P/B比率 変化
2026 (TTM) 4.21 6.80%
2025 3.94 -27.38%
2024 5.43 44.67%
2023 3.75 -8.59%
2022 4.11 -64.62%
2021 11.60 -41.84%
2020 19.95 52.81%
2019 13.06 -17.71%
2018 15.87 -20.12%
2017 19.87 32.34%
2016 15.01 -0.22%
2015 15.04 47.75%
2014 10.18 1.25%
2013 10.06 70.32%
2012 5.91 28.39%
2011 4.60 -10.55%
2010 5.14 17.45%
2009 4.38 -40.16%
2008 7.31 -12.44%
2007 8.35 25.21%
2006 6.67 58.64%
2005 4.21 53.56%
2004 2.74 23.37%
2003 2.22 -67.73%
2002 6.88 -56.70%
2001 15.89 71.69%
2000 9.25 0.00%
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
6.251 48.55%
US
13.2547 214.99%
US
- -
CH
6.1824 46.92%
NL
3.2932 -21.74%
BE